Overview

* Net loss for Q3 widened to $7.2 mln, driven by increased R&D expenses

* Company anticipates pivotal trial results for laromestrocel in 2026, potential BLA submission in 2027

Result Drivers

* REVENUE DECLINE - Decrease in revenue driven by reduced demand for Bahamas Registry Trial and contract manufacturing services

* R&D EXPENSES - Increase in R&D expenses due to higher personnel costs and technology transfer activities

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.39

Q3 Net -$7.22

Income mln

Q3 Gross $125,000

Profit

Q3 -$7.31

Income mln

from

Operatio

ns

Q3 $7.43

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Longeveron Inc ( LGVN ) is $7.00, about 88.1% above its November 3 closing price of $0.83

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)